Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches.

Femia D, Prinzi N, Anichini A, Mortarini R, Nichetti F, Corti F, Torchio M, Peverelli G, Pagani F, Maurichi A, Mattavelli I, Milione M, Bedini N, Corti A, Di Bartolomeo M, de Braud F, Pusceddu S.

Target Oncol. 2018 Aug 2. doi: 10.1007/s11523-018-0585-y. [Epub ahead of print]

PMID:
30073632
2.

The non-small cell lung cancer immune landscape: emerging complexity, prognostic relevance and prospective significance in the context of immunotherapy.

Anichini A, Tassi E, Grazia G, Mortarini R.

Cancer Immunol Immunother. 2018 Jun;67(6):1011-1022. doi: 10.1007/s00262-018-2147-7. Epub 2018 Mar 7. Review.

PMID:
29516154
3.

Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer.

Tassi E, Grazia G, Vegetti C, Bersani I, Bertolini G, Molla A, Baldassari P, Andriani F, Roz L, Sozzi G, Pastorino U, Mortarini R, Anichini A.

Cancer Res. 2017 Feb 15;77(4):851-861. doi: 10.1158/0008-5472.CAN-16-1387. Epub 2016 Dec 15.

4.

Brentuximab Vedotin in CD30-Expressing Germ Cell Tumors After Chemotherapy Failure.

Necchi A, Anichini A, Raggi D, Giannatempo P, Magazzù D, Nicolai N, Colecchia M, Paolini B, Coradeschi E, Tassi E, Grazia G, Mortarini R, Calareso G, De Fato R, Togliardi E, Crippa F, Salvioni R, Valagussa P, Gianni AM.

Clin Genitourin Cancer. 2016 Aug;14(4):261-264.e4. doi: 10.1016/j.clgc.2016.03.020. Epub 2016 Mar 24. No abstract available.

PMID:
27105722
5.

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

Penna I, Molla A, Grazia G, Cleris L, Nicolini G, Perrone F, Picciani B, Del Vecchio M, de Braud F, Mortarini R, Anichini A.

Oncotarget. 2016 Jan 26;7(4):3947-65. doi: 10.18632/oncotarget.6600.

6.

NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Perotti V, Baldassari P, Molla A, Vegetti C, Bersani I, Maurichi A, Santinami M, Anichini A, Mortarini R.

Oncogene. 2016 Jun 2;35(22):2862-72. doi: 10.1038/onc.2015.355. Epub 2015 Sep 21.

PMID:
26387540
7.

Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.

Loria R, Bon G, Perotti V, Gallo E, Bersani I, Baldassari P, Porru M, Leonetti C, Di Carlo S, Visca P, Brizzi MF, Anichini A, Mortarini R, Falcioni R.

Oncotarget. 2015 Feb 20;6(5):2779-93.

8.

Enrichment of CD56(dim)KIR + CD57 + highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients.

Ali TH, Pisanti S, Ciaglia E, Mortarini R, Anichini A, Garofalo C, Tallerico R, Santinami M, Gulletta E, Ietto C, Galgani M, Matarese G, Bifulco M, Ferrone S, Colucci F, Moretta A, Kärre K, Carbone E.

Nat Commun. 2014 Dec 4;5:5639. doi: 10.1038/ncomms6639.

9.

Synergistic anti-tumor activity and inhibition of angiogenesis by cotargeting of oncogenic and death receptor pathways in human melanoma.

Grazia G, Vegetti C, Benigni F, Penna I, Perotti V, Tassi E, Bersani I, Nicolini G, Canevari S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A.

Cell Death Dis. 2014 Oct 2;5:e1434. doi: 10.1038/cddis.2014.410.

10.

Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Mortarini R, Viviani S, Russo D, Marchianò A, Sorasio R, Dodero A, Farina L, Giordano L, Di Nicola M, Anichini A, Corradini P, Gianni AM.

Clin Cancer Res. 2014 Nov 15;20(22):5641-51. doi: 10.1158/1078-0432.CCR-14-0770. Epub 2014 Sep 19.

11.

Molecular subtyping of metastatic melanoma based on cell ganglioside metabolism profiles.

Tringali C, Silvestri I, Testa F, Baldassari P, Anastasia L, Mortarini R, Anichini A, López-Requena A, Tettamanti G, Venerando B.

BMC Cancer. 2014 Aug 1;14:560. doi: 10.1186/1471-2407-14-560.

12.

Prediction of survival in patients with thin melanoma: results from a multi-institution study.

Maurichi A, Miceli R, Camerini T, Mariani L, Patuzzo R, Ruggeri R, Gallino G, Tolomio E, Tragni G, Valeri B, Anichini A, Mortarini R, Moglia D, Pellacani G, Bassoli S, Longo C, Quaglino P, Pimpinelli N, Borgognoni L, Bergamaschi D, Harwood C, Zoras O, Santinami M.

J Clin Oncol. 2014 Aug 10;32(23):2479-85. doi: 10.1200/JCO.2013.54.2340. Epub 2014 Jul 7.

13.

Role of macrophage targeting in the antitumor activity of trabectedin.

Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P.

Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.

14.

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.

Locatelli SL, Giacomini A, Guidetti A, Cleris L, Mortarini R, Anichini A, Gianni AM, Carlo-Stella C.

Leukemia. 2013 Aug;27(8):1677-87. doi: 10.1038/leu.2013.28. Epub 2013 Jan 30.

PMID:
23360848
15.

NFATc2 is a potential therapeutic target in human melanoma.

Perotti V, Baldassari P, Bersani I, Molla A, Vegetti C, Tassi E, Dal Col J, Dolcetti R, Anichini A, Mortarini R.

J Invest Dermatol. 2012 Nov;132(11):2652-60. doi: 10.1038/jid.2012.179. Epub 2012 Jun 21.

16.

IGKV3 proteins as candidate "off-the-shelf" vaccines for kappa-light chain-restricted B-cell non-Hodgkin lymphomas.

Martorelli D, Guidoboni M, De Re V, Muraro E, Turrini R, Merlo A, Pasini E, Caggiari L, Romagnoli L, Spina M, Mortarini R, Gasparotto D, Mazzucato M, Carbone A, Rosato A, Anichini A, Dolcetti R.

Clin Cancer Res. 2012 Aug 1;18(15):4080-91. doi: 10.1158/1078-0432.CCR-12-0763. Epub 2012 Jun 15.

17.

Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

Guidetti A, Carlo-Stella C, Locatelli SL, Malorni W, Pierdominici M, Barbati C, Mortarini R, Devizzi L, Matteucci P, Marchianò A, Lanocita R, Farina L, Dodero A, Tarella C, Di Nicola M, Corradini P, Anichini A, Gianni AM.

Br J Haematol. 2012 Jul;158(1):108-19. doi: 10.1111/j.1365-2141.2012.09139.x. Epub 2012 May 10.

PMID:
22571717
18.

Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.

Tassi E, Zanon M, Vegetti C, Molla A, Bersani I, Perotti V, Pennati M, Zaffaroni N, Milella M, Ferrone S, Carlo-Stella C, Gianni AM, Mortarini R, Anichini A.

Clin Cancer Res. 2012 Jun 15;18(12):3316-27. doi: 10.1158/1078-0432.CCR-11-2232. Epub 2012 May 2.

19.

T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanoma.

Del Vecchio M, Mortarini R, Tragni G, Di Guardo L, Bersani I, Di Tolla G, Agustoni F, Colonna V, Weber JS, Anichini A.

J Clin Oncol. 2011 Nov 10;29(32):e783-8. doi: 10.1200/JCO.2011.36.5957. Epub 2011 Oct 11. No abstract available.

PMID:
21990398
20.

Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.

Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, Bedognetti D, Queirolo P, Morosini P, Perrone T, Bajetta E, Anichini A.

Clin Cancer Res. 2010 Dec 1;16(23):5862-72. doi: 10.1158/1078-0432.CCR-10-2363. Epub 2010 Oct 28. Erratum in: Clin Cancer Res. 2011 Feb 1;17(3):630.

21.

Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.

Anichini A, Molla A, Vegetti C, Bersani I, Zappasodi R, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Pircher H, Di Nicola M, Mortarini R.

Cancer Res. 2010 Nov 1;70(21):8378-87. doi: 10.1158/0008-5472.CAN-10-2028. Epub 2010 Sep 21.

22.

Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage.

Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, Patuzzo R, Santinami M, Anichini A.

Clin Cancer Res. 2009 Jun 15;15(12):4085-94. doi: 10.1158/1078-0432.CCR-08-3323. Epub 2009 Jun 9.

23.

Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.

Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, Ravagnani F, Cabras A, Anichini A, Gianni AM.

Blood. 2009 Jan 1;113(1):18-27. doi: 10.1182/blood-2008-06-165654. Epub 2008 Sep 22.

24.

The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells.

Zappasodi R, Di Nicola M, Carlo-Stella C, Mortarini R, Molla A, Vegetti C, Albani S, Anichini A, Gianni AM.

Haematologica. 2008 Oct;93(10):1523-34. doi: 10.3324/haematol.12521. Epub 2008 Aug 25.

25.

Regulation of breast cancer response to chemotherapy by fibulin-1.

Pupa SM, Giuffré S, Castiglioni F, Bertola L, Cantú M, Bongarzone I, Baldassari P, Mortarini R, Argraves WS, Anichini A, Menard S, Tagliabue E.

Cancer Res. 2007 May 1;67(9):4271-7.

26.

Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand.

Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, Mortarini R, Kaufmann GF, Zhou B, Felding-Habermann B, Janda KD.

Biochemistry. 2006 Aug 8;45(31):9434-44.

PMID:
16878978
27.

Association of antigen-processing machinery and HLA antigen phenotype of melanoma cells with survival in American Joint Committee on Cancer stage III and IV melanoma patients.

Anichini A, Mortarini R, Nonaka D, Molla A, Vegetti C, Montaldi E, Wang X, Ferrone S.

Cancer Res. 2006 Jun 15;66(12):6405-11.

28.

Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.

Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, Molla A, Vegetti C, Nonaka D, Mortarini R, Parmiani G, Fais S, Anichini A.

Oncogene. 2006 Jun 8;25(24):3357-64. Epub 2006 Feb 6.

PMID:
16462768
29.

Skewed T-cell differentiation in patients with indolent non-Hodgkin lymphoma reversed by ex vivo T-cell culture with gammac cytokines.

Anichini A, Mortarini R, Romagnoli L, Baldassari P, Cabras A, Carlo-Stella C, Gianni AM, Di Nicola M.

Blood. 2006 Jan 15;107(2):602-9. Epub 2005 Sep 8.

30.

APAF-1 signaling in human melanoma.

Anichini A, Mortarini R, Sensi M, Zanon M.

Cancer Lett. 2006 Jul 18;238(2):168-79. Epub 2005 Aug 10. Review.

PMID:
16095810
31.

Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles.

Mortarini R, Scarito A, Nonaka D, Zanon M, Bersani I, Montaldi E, Pennacchioli E, Patuzzo R, Santinami M, Anichini A.

Cancer Res. 2005 Apr 15;65(8):3428-36.

32.

Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.

Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, Ravagnani F, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A.

Clin Cancer Res. 2004 Aug 15;10(16):5381-90.

33.

The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma.

Anichini A, Vegetti C, Mortarini R.

Cancer Immunol Immunother. 2004 Oct;53(10):855-64. Epub 2004 Jun 3. Review.

PMID:
15175905
34.

Immunological and pathobiological roles of fibulin-1 in breast cancer.

Pupa SM, Argraves WS, Forti S, Casalini P, Berno V, Agresti R, Aiello P, Invernizzi A, Baldassari P, Twal WO, Mortarini R, Anichini A, Ménard S.

Oncogene. 2004 Mar 18;23(12):2153-60. Erratum in: Oncogene. 2004 Aug 19;23(37):6325. Argraves SW [corrected to Argraves WS].

PMID:
14691454
35.

Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection.

Di Nicola M, Napoli S, Anichini A, Mortarini R, Romagnoli L, Magni M, Matteucci P, Baldassarri P, Bersani I, Carlo-Stella C, Gianni AM.

Haematologica. 2003 Dec;88(12):1396-404.

36.

Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.

Di Nicola M, Carlo-Stella C, Anichini A, Mortarini R, Guidetti A, Tragni G, Gallino F, Del Vecchio M, Ravagnani F, Morelli D, Chaplin P, Arndtz N, Sutter G, Drexler I, Parmiani G, Cascinelli N, Gianni AM.

Hum Gene Ther. 2003 Sep 20;14(14):1347-60. No abstract available.

PMID:
14503969
37.

Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.

Anichini A, Scarito A, Molla A, Parmiani G, Mortarini R.

J Immunol. 2003 Aug 15;171(4):2134-41.

38.

Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, Lombardo C, Ravagnani F, Cascinelli N, Parmiani G, Anichini A.

Cancer Res. 2003 May 15;63(10):2535-45.

39.

Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction.

Rivoltini L, Carrabba M, Huber V, Castelli C, Novellino L, Dalerba P, Mortarini R, Arancia G, Anichini A, Fais S, Parmiani G.

Immunol Rev. 2002 Oct;188:97-113. Review.

PMID:
12445284
40.

Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?

Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, Anichini A.

J Natl Cancer Inst. 2002 Jun 5;94(11):805-18. Review.

PMID:
12048268
41.
42.

Large-scale feasibility of gene transduction into human CD34+ cell-derived dendritic cells by adenoviral/polycation complex.

Di Nicola M, Carlo-Stella C, Milanesi M, Magni M, Longoni P, Mortarini R, Anichini A, Tomanin R, Scarpa M, Gianni AM.

Br J Haematol. 2000 Oct;111(1):344-50.

PMID:
11091223
43.

Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12.

Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A.

Cancer Res. 2000 Jul 1;60(13):3559-68.

44.

The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity.

Morini M, Mottolese M, Ferrari N, Ghiorzo F, Buglioni S, Mortarini R, Noonan DM, Natali PG, Albini A.

Int J Cancer. 2000 Aug 1;87(3):336-42.

46.

High frequency of T cell clonal expansions in primary human melanoma. Involvement of a dominant clonotype in autologous tumor recognition.

Pisarra P, Mortarini R, Salvi S, Anichini A, Parmiani G, Sensi M.

Cancer Immunol Immunother. 1999 Apr;48(1):39-46.

PMID:
10235487
47.

Human dendritic cells: natural adjuvants in antitumor immunotherapy.

Di Nicola M, Anichini A, Mortarini R, Bregni M, Parmiani G, Gianni AM.

Cytokines Cell Mol Ther. 1998 Dec;4(4):265-73. Review.

PMID:
10068060
48.

Gene transfer into human dendritic antigen-presenting cells by vaccinia virus and adenovirus vectors.

Di Nicola M, Siena S, Bregni M, Longoni P, Magni M, Milanesi M, Matteucci P, Mortarini R, Anichini A, Parmiani G, Drexler I, Erfle V, Sutter G, Gianni AM.

Cancer Gene Ther. 1998 Nov-Dec;5(6):350-6.

PMID:
9917089
49.

Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma.

Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G.

Clin Cancer Res. 1998 Jan;4(1):75-85.

50.

Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides.

Benelli R, Mortarini R, Anichini A, Giunciuglio D, Noonan DM, Montalti S, Tacchetti C, Albini A.

AIDS. 1998 Feb 12;12(3):261-8.

PMID:
9517988

Supplemental Content

Loading ...
Support Center